
## Adaptimmune Therapeutics plc (Thu, Apr 25, 2024)

Sell candidate since Apr 02, 2024 Loss -24.29%



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

#16192/30099

Trend MV Long: MV Short: Volume: MACD:

## **Tech commentaries:**

The Adaptimmune Therapeutics plc stock price fell by -1.85% on the last day (Thursday, 25th Apr 2024) from \$1.08 to \$1.06. During the last trading day the stock fluctuated 5.69% from a day low at \$1.04 to a day high of \$1.10. The price has fallen in 7 of the last 10 days and is down by -17.83% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -203 thousand shares and in total, 565 thousand shares were bought and sold for approximately \$598.77 thousand.

The stock is moving within a very wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect Adaptimmune Therapeutics plc stock with a 90% probability to be traded between \$0.779 and \$1.80 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

There are mixed signals in the stock today. The Adaptimmune Therapeutics plc stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the long-term average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at \$1.34. On a fall, the stock will find some support from the short-term average at \$1.02. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Friday, March 08, 2024, and so far it has fallen -39.43%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

On the downside, the stock finds support just below today's level from accumulated volume at \$1.00 and \$0.96. On the upside the stock meets some resistance from accumulated volume at \$1.16, \$1.17 and \$1.25.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved \$0.0592 between high and low, or 5.69%. For the last week the stock has had daily average volatility of 11.86%.

Adaptimmune Therapeutics plc holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Risk: Very High

**Evaluation: Sell Candidate**